title: Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis.
abstract: The aim of this study was to analyze the change of serum chemokins levels of CXCL16, CX3CL1/Fractalkine, and CXCL10/interferon-gamma inducible protein-10 (IP-10) with rheumatoid arthritis (RA), by infliximab treatment. The effects of infliximab treatment were studied in 23 patients with RA, over a period of 30 weeks. The serum levels of CXCL16, Fractalkine, and IP-10, were measured at the baseline, just before initial treatment, and at 14 and 30 weeks after the initial treatment, with infliximab by ELISA. The higher levels of serum CXCL16 in the RA patients before treatment with infliximab significantly decreased at 14 and 30 weeks after the initial treatment with infliximab, but the serum Fractalkine and IP-10 levels did not decrease significantly. Infliximab treatment significantly lowered the serum levels of CXCL16 in patients with RA. CXCL16 is one of the crucial chemokines regulated by infliximab treatment.
authors.affiliation: Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Japan. Tsukatonpipi@nifty.com
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Kageyama
authors.forename: Eiji
authors.initials: E
authors.lastname: Torikai
authors.forename: Akira
authors.initials: A
authors.lastname: Nagano
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D054428:Chemokine CX3CL1 / Q000187:drug effects; D054357:Chemokine CXCL10 / Q000187:drug effects; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC / Q000097:blood / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D051116:Receptors, Scavenger / Q000097:blood / Q000187:drug effects*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; C423727:CXCL16 protein, human; D054428:Chemokine CX3CL1; D054357:Chemokine CXCL10; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC; D007155:Immunologic Factors; D051116:Receptors, Scavenger; D011239:Prednisolone; D000069285:Infliximab